Preparing developing countries for efficacy trials

Area of Science:

• Global health
• Vaccinology
• Epidemiology

Background:

• The AIDS epidemic in Africa is a critical global health crisis.
• Over two decades since HIV discovery, effective biomedical interventions remain elusive.
• Two candidate vaccines targeting human immunodeficiency virus (HIV) are set for efficacy testing in Africa.

Purpose of the Study:

• To review challenges and developments for conducting HIV vaccine efficacy trials in developing countries.
• To outline epidemiologic, scientific, site development, and standard of care considerations.
• To prepare for the first-ever continent-wide HIV vaccine efficacy trials.

Main Methods:

• Review of recent developments in HIV vaccine research and trial implementation.
• Analysis of scientific, logistic, regulatory, and ethical challenges.
• Consideration of epidemiologic factors and standard of care in developing countries.

Main Results:

• Two adenovirus type 5-vectored HIV vaccine candidates will undergo efficacy testing.
• Vaccines aim to elicit cytotoxic T lymphocyte responses, potentially ameliorating infection and reducing transmission.
• Efficacy may be influenced by pre-existing immunity to vectors and HIV genetic diversity.

Conclusions:

• HIV vaccine efficacy trials are imminent in Africa.
• Enrollment of young women and adolescents in high-incidence areas is crucial.
• Developing clinical trial capacity, transferring technology, and ensuring robust regulatory/ethical review are paramount.